Valeo Financial Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.85M | Buy |
9,817
+1,316
| +15% | +$248K | 0.04% | 194 |
|
|
2026
Q1 | $1.68M | Sell |
8,501
-1,167
| -12% | -$225K | 0.04% | 183 |
|
|
2025
Q4 | $1.78M | Buy |
9,668
+654
| +7% | +$115K | 0.04% | 192 |
|
|
2025
Q3 | $1.38M | Buy |
9,014
+234
| +3% | +$35.4K | 0.03% | 231 |
|
|
2025
Q2 | $1.23M | Buy |
8,780
+984
| +13% | +$138K | 0.03% | 253 |
|
|
2025
Q1 | $1.15M | Buy |
7,796
+503
| +7% | +$72.8K | 0.03% | 236 |
|
|
2024
Q4 | $956K | Sell |
7,293
-536
| -7% | -$75K | 0.03% | 278 |
|
|
2024
Q3 | $1.22M | Sell |
7,829
-236
| -3% | -$38.1K | 0.03% | 226 |
|
|
2024
Q2 | $1.26M | Buy |
8,065
+35
| +0.4% | +$5.27K | 0.04% | 203 |
|
|
2024
Q1 | $1.14M | Buy |
8,030
+469
| +6% | +$62.1K | 0.04% | 214 |
|
|
2023
Q4 | $1.02M | Sell |
7,561
-768
| -9% | -$99.8K | 0.04% | 219 |
|
|
2023
Q3 | $1.13M | Sell |
8,329
-172
| -2% | -$23.5K | 0.05% | 188 |
|
|
2023
Q2 | $1.22M | Buy |
8,501
+543
| +7% | +$79.9K | 0.06% | 181 |
|
|
2023
Q1 | $1.1M | Buy |
7,958
+1,152
| +17% | +$155K | 0.05% | 197 |
|
|
2022
Q4 | $923K | Buy |
6,806
+1,868
| +38% | +$234K | 0.05% | 197 |
|
|
2022
Q3 | $542K | Sell |
4,938
-74
| -1% | -$9.39K | 0.03% | 253 |
|
|
2022
Q2 | $662K | Sell |
5,012
-305
| -6% | -$40K | 0.04% | 211 |
|
|
2022
Q1 | $705K | Buy |
5,317
+464
| +10% | +$55.6K | 0.04% | 257 |
|
|
2021
Q4 | $565K | Sell |
4,853
-43
| -0.9% | -$5.06K | 0.03% | 279 |
|
|
2021
Q3 | $588K | Buy |
+4,896
| New | +$570K | 0.03% | 268 |
|
|
2021
Q2 | – | Sell |
-1,355
| Closed | -$135K | – | 634 |
|
|
2021
Q1 | $135K | Sell |
1,355
-185
| -12% | -$18.6K | 0.01% | 538 |
|
|
2020
Q4 | $154K | Buy |
1,540
+34
| +2% | +$3.6K | 0.01% | 465 |
|
|
2020
Q3 | $165K | Sell |
1,506
-312
| -17% | -$34.7K | 0.01% | 359 |
|
|
2020
Q2 | $192K | Buy |
1,818
+518
| +40% | +$53.5K | 0.02% | 327 |
|
|
2020
Q1 | $116K | Buy |
1,300
+37
| +3% | +$3.48K | 0.01% | 391 |
|
|
2019
Q4 | $126K | Sell |
1,263
-10
| -0.8% | -$941 | 0.01% | 410 |
|
|
2019
Q3 | $113K | Sell |
1,273
-725
| -36% | -$62.9K | 0.01% | 405 |
|
|
2019
Q2 | $165K | Hold |
1,998
| – | – | 0.02% | 323 |
|
|
2019
Q1 | $162K | Hold |
1,998
| – | – | 0.02% | 324 |
|
|
2018
Q4 | $152K | Buy |
1,998
+95
| +5% | +$7.42K | 0.02% | 298 |
|
|
2018
Q3 | $147K | Sell |
1,903
-107
| -5% | -$8.09K | 0.02% | 326 |
|
|
2018
Q2 | $157K | Sell |
2,010
-1,102
| -35% | -$79.3K | 0.02% | 316 |
|
|
2018
Q1 | $218K | Buy |
3,112
+842
| +37% | +$58.3K | 0.04% | 249 |
|
|
2017
Q4 | $158K | Buy |
2,270
+313
| +16% | +$21.1K | 0.03% | 271 |
|
|
2017
Q3 | $133K | Buy |
+1,957
| New | +$124K | 0.03% | 251 |
|
Other funds holding AZN
EP
IA
Valeo Financial Advisors's AZN Position: Q2 2026 in Review
Valeo Financial Advisors increased its AstraZeneca (AZN) stake by 15% in Q2 2026, buying an estimated $248K and bringing the position to 9,817 shares worth $1.85M. The position accounts for 0.04% of the portfolio, ranked #194.
Valeo Financial Advisors first reported a position in AZN in Q3 2017 and has held it in 35 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Valeo Financial Advisors held 9,817 shares of AstraZeneca worth $1.85M as of Q2 2026.
- Valeo Financial Advisors bought 1,316 AstraZeneca shares in Q2 2026, an estimated $248K.
- AstraZeneca made up 0.04% of Valeo Financial Advisors's portfolio in Q2 2026, its #194 holding.
- Valeo Financial Advisors first reported a position in AstraZeneca in Q3 2017 and has held it in 35 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Valeo Financial Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.